ATC codes: J01DI54
Carbapenem-resistant Pseudomonas aeruginosa ICD11 code: MG50.80
Ceftolozane + tazobactam
Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
Also recommended for children
The recommendation is for this specific medicine
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of ceftolozane + tazobactam as Reserve group antibiotic on the complementary list of the EML and EMLc for the treatment of infections caused or suspected to be caused by carbapenem-resistant Pseudomonas aeruginosa, a “Critical” priority pathogen on the 2017 WHO Priority Pathogens List. The Committee acknowledged that the clinical evidence for efficacy of ceftolozane + tazobactam against this specific pathogen is limited but considered that the availability of carbapenem-sparing alternatives for treatment of drug-resistant Pseudomonas aeruginosa was important as part of the strategy to limit/prevent further emergence and spread of carbapenem-resistant organisms.